Payment overview · 2025
General Payments
$271.41
3 reported records · 2 companies
Healthcare provider profile · identity verified
Adib Rushdan, MD
Allopathic & Osteopathic Physicians|Family Medicine · READING, PA · NPI 1932692746
Verified facts
What the public records show
CMS Open Payments records show Adib Rushdan, MD received $271.41 in general payments during 2025 across 3 reported records.
Insulet Corporation accounted for 94.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Insulet Corporation | Unresolved — no canonical attribution shown | $255.42 | 94.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.99 | 5.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $255.42 | 2 |
| Education | $15.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OMNIPOD Normalized: omnipod |
Device | Insulet Corporation | $255.42 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
53 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 496 | 195 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 334 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 267 | 120 |
| Gabapentin | Gabapentin | 221 | 75 |
| Losartan Potassium | Losartan Potassium | 204 | 73 |
| Metformin Hcl | Metformin Hcl | 181 | 71 |
| Omeprazole | Omeprazole | 172 | 61 |
| Lisinopril | Lisinopril | 170 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 151 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 143 | 58 |
| Famotidine | Famotidine | 127 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 119 | 43 |
| Furosemide | Furosemide | 104 | 40 |
| Januvia | Sitagliptin Phosphate | 95 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 94 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 39 |
| Carvedilol | Carvedilol | 86 | 33 |
| Eliquis | Apixaban | 83 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 29 |
| Montelukast Sodium | Montelukast Sodium | 78 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 78 | 34 |
| Prednisone | Prednisone | 76 | 47 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 36 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 27 |
| Meloxicam | Meloxicam | 68 | 23 |
| Trazodone Hcl | Trazodone Hcl | 68 | 33 |
| Ibuprofen | Ibuprofen | 66 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 21 |
| Sertraline Hcl | Sertraline Hcl | 59 | 20 |
| Tramadol Hcl | Tramadol Hcl | 56 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 14 |
| Farxiga | Dapagliflozin Propanediol | 53 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 12 |
| Ozempic | Semaglutide | 53 | 20 |
| Potassium Chloride | Potassium Chloride | 53 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 51 | 14 |
| Alendronate Sodium | Alendronate Sodium | 49 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 15 |
| Nystatin | Nystatin | 49 | 19 |
| Metformin Hcl Er | Metformin Hcl | 47 | 20 |
| Glimepiride | Glimepiride | 46 | 15 |
| Naproxen | Naproxen | 46 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 15 |
| Bupropion Xl | Bupropion Hcl | 40 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 40 | 13 |
| Simvastatin | Simvastatin | 40 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 17 |
| Trulicity | Dulaglutide | 40 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 13 |
| Mometasone Furoate | Mometasone Furoate | 38 | 12 |
| Meclizine Hcl | Meclizine Hcl | 37 | 14 |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 15 |
| Mirtazapine | Mirtazapine | 36 | 16 |
| Nitroglycerin | Nitroglycerin | 36 | 15 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 35 | suppressed |
| Linzess | Linaclotide | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | 15 |
| Chlorthalidone | Chlorthalidone | 34 | 11 |
| Donepezil Hcl | Donepezil Hcl | 34 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 34 | 13 |
| Baclofen | Baclofen | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 32 | 16 |
| Ondansetron Odt | Ondansetron | 32 | 16 |
| Ezetimibe | Ezetimibe | 31 | 16 |
| Nifedipine Er | Nifedipine | 31 | 12 |
| Allopurinol | Allopurinol | 30 | suppressed |
| Clotrimazole | Clotrimazole | 30 | suppressed |
| Glipizide | Glipizide | 30 | 14 |
| Topiramate | Topiramate | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Azithromycin | Azithromycin | 25 | 22 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | 11 |
| Ammonium Lactate | Ammonium Lactate | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Jardiance | Empagliflozin | 21 | 11 |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 13 |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 12 |
| Glipizide Er | Glipizide | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 11 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 14 |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $271.41 · 3 records | Insulet Corporation | BREZTRI, OMNIPOD | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error